Pilot study of algorithms implementation package for Chronic Pain

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Chronic Pain+2 More
Pilot study of algorithms implementation package - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test strategies to help people with chronic pain who are misusing opioids.

Eligible Conditions
  • Chronic Pain
  • Opioids

Treatment Effectiveness

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 1 year

1 year
Acceptability of algorithms
Feasibility of algorithms
Preliminary Effectiveness of algorithms

Trial Safety

Trial Design

1 Treatment Group

Implementation bundle
1 of 1

Experimental Treatment

80 Total Participants · 1 Treatment Group

Primary Treatment: Pilot study of algorithms implementation package · No Placebo Group · N/A

Implementation bundle
Behavioral
Experimental Group · 1 Intervention: Pilot study of algorithms implementation package · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,228 Previous Clinical Trials
5,615,331 Total Patients Enrolled
47 Trials studying Chronic Pain
61,895 Patients Enrolled for Chronic Pain
University of PittsburghLead Sponsor
1,601 Previous Clinical Trials
6,286,244 Total Patients Enrolled
15 Trials studying Chronic Pain
128,823 Patients Enrolled for Chronic Pain
Jessica MerlinPrincipal InvestigatorUniversity of Pittsburgh

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: November 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.